Attached files
| file | filename |
|---|---|
| EX-99.1 - POSTER TITLED THE NATURE AND PREVALENCE OF MIDDLE-OF-THE-NIGHT-HYPNOTIC USE - Paratek Pharmaceuticals, Inc. | dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
May 16, 2011 (May 14, 2011)
Date of Report (date of earliest event reported)
TRANSCEPT PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
| Delaware | 000-51967 | 33-0960223 | ||
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) | (I.R.S. Employer Identification Number) |
1003 W. Cutting Blvd., Suite #110
Point Richmond, California 94804
(Address of principal executive offices)
(510) 215-3500
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 7.01 | Regulation FD Disclosure. |
The information in the poster attached hereto as Exhibit 99.1 titled The Nature and Prevalence of Middle-of-the-Night-Hypnotic Use was presented at the Society of Biological Psychiatry 66th Annual Meeting on May 14, 2011 in San Francisco, California. The poster was sponsored by Transcept Pharmaceuticals, Inc.
The furnishing of the attached poster is not an admission as to the materiality of any information therein. The information in Item 7.01 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No.
|
Description
| |
| 99.1 |
Poster titled The Nature and Prevalence of Middle-of-the-Night-Hypnotic Use | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TRANSCEPT PHARMACEUTICALS, INC. | ||||||
| Date: May 16, 2011 | ||||||
| By: | /s/ Marilyn E. Wortzman | |||||
| Name: Marilyn E. Wortzman | ||||||
| Title: Vice President, Finance | ||||||
EXHIBIT INDEX
| Exhibit No. |
Description
| |
| 99.1 | Poster titled The Nature and Prevalence of Middle-of-the-Night-Hypnotic Use | |